O T C
Nutra Pharma Announces that Diverse Health Services has Added Nyloxin to Their Product Offerings

  Diverse Health Services, an industry leader in Chiropractic care and Alternative Medicine, announced the addition of the Nyloxin® line of pain relief products to their marketplace   Plantation, Florida, June 8, 2021 — Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™, and Equine Pain-Away™ in the over-the-counter (OTC)

Nutra Pharma Announces Private Label Expansion of their Over-The-Counter Pain Relievers

  Plantation, Florida, June 4, 2021 – Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away, Luxury Feet and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today their plans for increasing sales

Professional Snowboarder Jake Vedder Joins Nutra Pharma in Endorsing Nyloxin for Chronic Pain Relief

  Nutra Pharma announces that professional snowboarder and wakeboarder, Jake Vedder, is endorsing Nyloxin for Chronic Pain Relief as part of their social media and influencer campaign   Plantation, Florida, June 2, 2021 — Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain

Nutra Pharma Provides Updates on Improvements of Manufacturing Capabilities

Nutra Pharma is providing updates on their work in improving manufacturing scale and capabilities for the production of their over-the-counter pain relievers   Plantation, Florida, May 27, 2021 — McapMediaWire — Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Equine Pain-Away™ and Luxury Feet™ in the over-the-counter (OTC) pain management

PAOG CBD Pharmaceutical Development Update Coming Tomorrow, Tuesday April 13, 2021

  Sandusky, OH, April 12, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today confirmed a management update on the company’s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is

SIBANNAC, INC. ANNOUNCES ENTRY INTO MEMORANDUM OF UNDERSTANDING TO ACQUIRE STELLAR CHEMICAL CORP.

  Scottsdale, Arizona, April 12, 2021 – OTC PR WIRE – Sibannac, Inc. (OTC Pink: SNNC), a Nevada corporation (the “Company”), announced the following: Sibannac, Inc. and Stellar Chemical Corp. (“Stellar”), a New Jersey based nutraceutical and industrial chemical manufacturer, have entered into a Memorandum of Understanding for Sibannac to acquire 51% of Stellar in

PAOG Advances CBD Pharmaceutical Developments Backed By US Patent

  Sandusky, OH, April 8, 2021 – OTC PR WIRE —  PAO Group, Inc. (OTC Pink: PAOG) today announced a management update on the company’s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is

Nutra Pharma Engages Quality and Regulatory Professionals Ahead of Clinical Trials

  Nutra Pharma is providing updates on their work in improving capabilities and certifications in their laboratory for drug production and validation in preparation of expanded OTC sales and clinical trials   Plantation, Florida,  March 11, 2021 — OTC PR WIRE — Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away

PAOG CBD RELAX-RX Co-Packing With ALKM And Marketing With USMJ Detailed In Update Scheduled Next Week

Sandusky, OH, March 9, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today announced an update scheduled one week from today, for Tuesday, March 16, 2021 to publish details on the company’s CBD RELAX-RX nutraceutical development plans including intended co-packing with Alkame Holdings, Inc. (OTC Pink: ALKM) and marketing with North

PAOG Announces RELAX-RX Nutraceutical For $18 Billion Anxiety And Depression Treatment Market

  Sandusky, OH, March 8, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today announced initiating the development of its new nutraceutical, RELAX-RX, targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The company recently announced plans to produce a variety of nutraceuticals

Recent Posts

Recent Posts

Contact Us

All Rights Reserved © 2019